Compare HNVR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | BDTX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 171.9M |
| IPO Year | 2022 | 2020 |
| Metric | HNVR | BDTX |
|---|---|---|
| Price | $23.73 | $1.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $24.50 | $9.67 |
| AVG Volume (30 Days) | 73.2K | ★ 1.9M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | N/A |
| Revenue Next Year | $8.61 | N/A |
| P/E Ratio | $93.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.60 |
| 52 Week High | $24.55 | $4.94 |
| Indicator | HNVR | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.78 | 45.28 |
| Support Level | $21.89 | $1.60 |
| Resistance Level | $24.34 | $2.30 |
| Average True Range (ATR) | 0.77 | 0.14 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 60.00 | 68.02 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.